Amrutanjan Healt

Why is Amrutanjan Health Care Ltd falling/rising?

As of 08-Aug, Amrutanjan Health Care Ltd's stock price is rising to 522.95 due to strong recent performance, including a 45.3% increase in profit after tax and record net sales. Despite a year-to-date decline, the stock may be undervalued with a PEG ratio of 0.9, although investor participation has significantly decreased.

As of 08-Aug, Amrutanjan Health Care Ltd's stock price is rising, currently at 522.95, reflecting a change of 3.05 (0.59%) upward. This increase can be attributed to the company's strong performance in recent quarters, as it has reported positive results for the last four consecutive quarters, including a significant growth in profit after tax (PAT) of 45.3% to Rs 22.05 crore and record net sales of Rs 149.77 crore. Additionally, the company maintains a high return on equity (ROE) of 18.42%, indicating efficient management.<BR><BR>Despite the stock's year-to-date decline of 21.73% and a one-year drop of 21.37%, the company's profits have risen by 27.2%, suggesting that the stock may be undervalued compared to its peers, as it is trading at a discount relative to average historical valuations. The stock's PEG ratio of 0.9 further supports this attractive valuation. Furthermore, the stock has outperformed its sector by 0.48% today, which may also contribute to the positive sentiment among investors. However, it is important to note that there has been a significant decline in investor participation, with delivery volume falling by 75.71% against the five-day average, which could indicate caution among some investors.

Which are the latest news on Amrutanjan Healt?

When is the next results date for Amrutanjan Health Care Ltd?

The next results date for Amrutanjan Health Care Ltd is August 11, 2026.

The next results date for Amrutanjan Health Care Ltd is scheduled for August 11, 2026.

How big is Amrutanjan Healt?

As of 10th June, Amrutanjan Health Care Ltd has a market capitalization of 1,619.00 Cr, with net sales of 502.56 Cr and net profit of 57.91 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Amrutanjan Health Care Ltd has a market capitalization of 1,619.00 Cr and is classified as a Small Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 502.56 Cr, while the sum of Net Profit for the same period is 57.91 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2016. Shareholder's Funds are valued at 108.74 Cr, and Total Assets amount to 140.44 Cr.

Who are in the management team of Amrutanjan Healt?

The management team of Amrutanjan Health includes S Sambhuprasad (Chairman and Managing Director), along with several independent and non-executive directors: Marie Shiranee Pereira, V Raja, Muralidharan Swayambunathan, Meena Lochani Raghunathan, and Ramaa Prabhakar Arikirevula, as well as M Srinivasan (Company Secretary & Compliance Officer).

The management team of Amrutanjan Health includes the following individuals:<BR><BR>1. **S Sambhuprasad** - Chairman and Managing Director (CMD) & Executive Director<BR>2. **Marie Shiranee Pereira** - Independent Non-Executive Director<BR>3. **V Raja** - Independent Non-Executive Director<BR>4. **Muralidharan Swayambunathan** - Independent Non-Executive Director<BR>5. **Meena Lochani Raghunathan** - Independent Non-Executive Director<BR>6. **Ramaa Prabhakar Arikirevula** - Non-Executive Director<BR>7. **M Srinivasan** - Company Secretary & Compliance Officer<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Amrutanjan Healt?

Amrutanjan Healt's peers include Indoco Remedies, NGL Fine Chem, Hester Bios, and others. It has Below Average growth and management risk, with a 1-year return of -19.65%, significantly lower than NGL Fine Chem's 161.05%.

Peers: The peers of Amrutanjan Healt are Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Ind-Swift Labs., Shukra Pharma., Jagsonpal Pharma, Syncom Formul., Beta Drugs Ltd, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at NGL Fine Chem, Windlas Biotech, Shukra Pharma., Jagsonpal Pharma, and Beta Drugs Ltd, while Average management risk is found at Indoco Remedies, Hester Bios, Ind-Swift Labs., and Syncom Formul., and the rest. Below Average management risk is noted for Ind-Swift Labs. Growth is rated as Excellent for Shukra Pharma., while Below Average growth is seen at Indoco Remedies, NGL Fine Chem, Hester Bios, Windlas Biotech, Amrutanjan Healt, Ind-Swift Labs., Jagsonpal Pharma, Syncom Formul., and the rest. Capital Structure is rated as Excellent for NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Shukra Pharma., Jagsonpal Pharma, Syncom Formul., and Beta Drugs Ltd, while Below Average is noted for Indoco Remedies, Hester Bios, Ind-Swift Labs., and the rest.<BR><BR>Return Snapshot: NGL Fine Chem has the highest 1-year return at 161.05%, while Amrutanjan Healt has the lowest at -19.65%. This indicates that Amrutanjan Healt's return is significantly lower than that of NGL Fine Chem. Additionally, Windlas Biotech, Amrutanjan Healt, and Syncom Formul. have negative six-month returns.

What does Amrutanjan Healt do?

Amrutanjan Health Care Ltd is a small-cap pharmaceutical company based in Chennai, specializing in bulk drugs and drug intermediates, with a market cap of INR 1,619 Cr and a net profit of 16 Cr as of March 2026. The company has a P/E ratio of 25.00 and a dividend yield of 0.82%.

Overview:<BR>Amrutanjan Health Care Ltd is a small-cap company operating in the Pharmaceuticals & Biotechnology industry, specializing in the manufacture of bulk drugs and drug intermediates.<BR><BR>History:<BR>Incorporated on September 9, 1936, in Chennai, Tamil Nadu, Amrutanjan Health Care Ltd has established itself in the pharmaceutical sector. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 150 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 16 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,619 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 25.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.82%<BR>- Debt Equity: -0.18<BR>- Return on Equity: 18.91%<BR>- Price to Book: 4.76<BR><BR>Contact Details:<BR>Address: New 103 Old 42-45 LuzChurch Rd, Mylapore Chennai Tamil Nadu : 600004<BR>Tel: 91-44-24994164/24994465/24994366<BR>Email: shares@amrutanjan.com<BR>Website: http://www.amrutanjan.com

Are Amrutanjan Health Care Ltd latest results good or bad?

Amrutanjan Health Care Ltd's latest Q4 FY26 results show strong revenue growth with net sales up 6.19% quarter-on-quarter, but profitability concerns arise as the PAT margin contracted significantly to 10.81%. Overall, while revenue performance is positive, the decline in margins raises caution about future profitability.

Amrutanjan Health Care Ltd's latest results for Q4 FY26 present a mixed picture. On the positive side, the company achieved a record net sales figure of ₹149.77 crores, reflecting a growth of 6.19% quarter-on-quarter and 10.60% year-on-year. This marks the seventh consecutive quarter of revenue expansion, indicating strong demand for its products, particularly in the pain relief segment.<BR><BR>However, profitability metrics reveal some concerns. The net profit for the quarter was ₹16.19 crores, which is a 6.67% increase from the previous quarter and a 6.65% increase year-on-year. Despite this growth, the profit after tax (PAT) margin contracted significantly to 10.81% from 13.79% in the previous quarter, suggesting pressure on profitability. This decline in margins is attributed to a normalization from an exceptionally strong December quarter.<BR><BR>Overall, while the revenue growth is commendable, the sharp contraction in margins raises questions about the sustainability of profitability in the face of competitive pressures. The stock has also underperformed the broader market, declining 20.54% over the past year compared to the Sensex's 3.74% fall, which reflects investor concerns about margin sustainability.<BR><BR>In summary, the results show strong revenue growth but highlight challenges in maintaining profitability, making the overall assessment somewhat cautious.

Should I buy, sell or hold Amrutanjan Health Care Ltd?

Has Amrutanjan Health Care Ltd declared dividend?

Yes, Amrutanjan Health Care Ltd has declared a 100% dividend, amounting to ₹1 per share, with an ex-date of February 6, 2026. While total returns have fluctuated, the company has shown positive returns over the 2 and 5-year periods.

Amrutanjan Health Care Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 100%<BR>- Amount per share: 1 per share<BR>- Ex-date: 06 Feb 26<BR><BR>Dividend Yield: 0.72%.<BR><BR>Total Returns by Period:<BR>In the 3 Months period, the price return was -12.24%, the dividend return was 0.28%, resulting in a total return of -11.96%.<BR><BR>In the 6 Months period, the price return was -8.61%, the dividend return was 0.70%, leading to a total return of -7.91%.<BR><BR>In the 1 Year period, the price return was -6.2%, the dividend return was 0.85%, resulting in a total return of -5.35%.<BR><BR>In the 2 Years period, the price return was 9.64%, the dividend return was 1.55%, leading to a total return of 11.19%.<BR><BR>In the 3 Years period, the price return was -10.97%, the dividend return was 2.35%, resulting in a total return of -8.62%.<BR><BR>In the 4 Years period, the price return was -24.41%, the dividend return was 2.20%, leading to a total return of -22.21%.<BR><BR>In the 5 Years period, the price return was 21.73%, the dividend return was 4.04%, resulting in a total return of 25.77%.<BR><BR>Overall, Amrutanjan Health Care Ltd has declared a significant dividend, and while the total returns have varied across different periods, the company has shown positive total returns over the longer 2, 5-year periods despite some negative returns in shorter durations.

Is Amrutanjan Healt technically bullish or bearish?

As of November 24, 2025, Amrutanjan Health's technical trend is mildly bearish, supported by bearish MACD readings, Bollinger Bands, and underperformance against the Sensex, despite some daily moving averages showing mild bullishness.

As of 24 November 2025, the technical trend for Amrutanjan Healt has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating mild bearishness, along with Bollinger Bands showing bearish signals in both time frames. The KST and Dow Theory also reflect a mildly bearish outlook on a weekly and monthly basis. Although daily moving averages are mildly bullish, the overall sentiment remains bearish due to the prevailing indicators. The stock has underperformed against the Sensex over multiple periods, further supporting the bearish stance.

How has been the historical performance of Amrutanjan Healt?

Amrutanjan Healt has demonstrated consistent growth in net sales and profits from 2011 to 2017, with net sales rising from 105.41 Cr to 231.70 Cr and profit after tax increasing from 10.43 Cr to 21.14 Cr, reflecting strong operational performance and improved financial stability.

Answer:<BR>The historical performance of Amrutanjan Healt shows a consistent growth trend in net sales and profits over the years, particularly from 2011 to 2017.<BR><BR>Breakdown:<BR>Amrutanjan Healt's net sales increased from 105.41 Cr in March 2011 to 231.70 Cr in March 2017, reflecting a strong upward trajectory. Other operating income also rose, contributing to total operating income growth from 105.41 Cr in 2011 to 234.59 Cr in 2017. The company's total expenditure, excluding depreciation, rose from 92.46 Cr in 2011 to 205.57 Cr in 2017, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) saw fluctuations, peaking at 36.34 Cr in March 2016 before slightly declining to 33.85 Cr in March 2017. Profit before tax increased from 15.60 Cr in 2011 to 33.24 Cr in 2017, while profit after tax reached 21.14 Cr in 2017, up from 10.43 Cr in 2011. The earnings per share (EPS) also improved from 3.44 in 2011 to 7.23 in 2017, demonstrating enhanced shareholder value. The company's total assets grew from 156.69 Cr in 2011 to 140.44 Cr in 2016, while total liabilities decreased from 30.80 Cr in 2011 to 2.50 Cr in 2016, indicating improved financial stability. Cash flow from operating activities increased significantly, showcasing the company's ability to generate cash from its operations, culminating in a closing cash balance of 42.42 Cr in March 2016. Overall, Amrutanjan Healt has shown a robust performance with increasing revenues and profits, alongside effective cost management.

Is Amrutanjan Healt overvalued or undervalued?

As of May 14, 2025, Amrutanjan Health is considered undervalued with an attractive valuation grade despite a short-term underperformance against the Sensex, showing a PE ratio of 40.54 and strong long-term growth potential with a five-year return of 105.48%.

As of 14 May 2025, the valuation grade for Amrutanjan Healt has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 40.54, an EV to EBITDA ratio of 34.03, and a ROCE of 21.05%. In comparison to its peers, Sun Pharma has a PE of 35.25 and EV to EBITDA of 24.91, while Cipla shows a more attractive PE of 22.99 and EV to EBITDA of 15.93, highlighting Amrutanjan's relatively high valuation metrics.<BR><BR>Despite its attractive valuation grade, Amrutanjan has underperformed against the Sensex in the short term, with a year-to-date stock return of -1.37% compared to the Sensex's 5.63%. However, its long-term performance remains strong, with a five-year return of 105.48%. Overall, the company appears to be positioned well within the pharmaceuticals and biotechnology sector, suggesting potential for future growth.

Who are the top shareholders of the Amrutanjan Healt?

The top shareholders of Amrutanjan Health include Goodhealth Holdings Private Limited with 20.15%, mutual funds holding 7.55%, foreign institutional investors at 2.3%, and individual investors collectively owning 33.56%. The largest public shareholder is DSP Small Cap Fund with a 5.07% stake.

The top shareholders of Amrutanjan Health include a mix of promoters, mutual funds, and individual investors. The largest promoter is Goodhealth Holdings Private Limited, which holds 20.15% of the shares. In terms of institutional investment, mutual funds collectively hold 7.55% across four schemes, while foreign institutional investors (FIIs) hold 2.3% through 28 different entities. The highest public shareholder is DSP Small Cap Fund, with a 5.07% stake. Additionally, individual investors collectively hold 33.56% of the company's shares.